Navigation Links
Canadian Cattle Producers Willing to Make Changes to Prevent E. coli O157 Contamination on their Farms
Date:3/16/2010

                 -survey conducted for Bioniche Food Safety-

BELLEVILLE, ON, March 16 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a survey conducted among a random sample of 771 Canadian beef and dairy farmers in all regions of Canada showed that the majority are willing to implement changes on the farm to prevent contamination by E. coli O157.

Bioniche Life Sciences Inc. has developed and licensed (in Canada) the world's first vaccine to reduce the shedding by cattle of E. coli O157. Econiche(TM) received full licensing approval from the Canadian Food Inspection Agency (CFIA) in October, 2008 and is available for unrestricted use by Canadian cattle producers and their veterinarians. The United States Department of Agriculture (USDA) cleared the path for a conditional license for the vaccine in February, 2008, and the Company is awaiting issuance of that license.

In the independently conducted survey, just over half of the producers surveyed expressed a willingness to vaccinate, but there was sensitivity to the potential cost of a vaccination program. Those surveyed believe the cost of a national vaccination program, if it were to be implemented, should be shared between government and producers, with 88% of respondents expressing willingness to vaccinate if the vaccine was provided free of charge. Their main reasons for supporting vaccination were: Food safety, the potential impact of recalls, and access to export markets.

"The use of chlorinated water, bacteriophages and probiotics help control the organisms, but vaccination provides the greatest reduction in fecal shedding," said Dr. Roy Lewis, a large animal veterinarian in Westlock, Alberta (in the January, 2010 issue of Canadian Cattlemen magazine). "With the vaccine, you are hitting the problem at its very source, before the bacteria numbers get too high."

Added Dr. Lewis: "Vaccination, together with all the other preventive steps, will hopefully keep this dreaded disease to a minimum and keep consumer confidence in our beef as high as possible."

Econiche is a Canadian discovery developed by Bioniche Life Sciences Inc. The vaccine has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle. This organism does not cause illness in cattle, but cattle are the primary reservoir for it. Most strains of E. coli are harmless but some, like O157:H7, can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. Vaccination of cattle with Econiche can help reduce the risk of food and waterborne contamination with E. coli O157.

On-farm interventions to reduce the shedding of E. coli O157 by cattle, such as simple vaccination of cattle with Econiche, have the potential to reduce food and water contamination and the consequences associated with human infection with the deadly bacteria.

The United States Department of Agriculture (USDA)'s Food Safety and Inspection Services (FSIS) developed a risk assessment method to estimate how much human illness caused by E. coli O157 can be prevented through the use of "pre-harvest interventions" such as vaccination (Streamlined Analysis for Evaluating the Use of Preharvest Interventions Intended to Prevent Escherichia coli O157:H7 Illness in Humans, Foodborne Pathogens and Disease, Volume 6, Number 7, 2009). Researchers created two economic production functions where the input was the number of vaccinated cattle and the output was human illness prevented. Although this was a hypothetical case study, it showed that, "... vaccinating the entire U.S. herd at a cost of between $2.29 and $9.14 per unit (depending on overall effectiveness of the vaccine) would be a cost-effective intervention for preventing E. coli O157:H7 illness in humans."

Human exposure and infection with E. coli O157:H7 can result in serious health consequences, including abdominal pain and severe bloody diarrhea. In severe cases, kidney damage can occur and progress to serious complications and even death. In one of the reported outbreaks, in Nestle Toll-House cookie dough, 76 persons from 31 states in the U.S. have been infected with E. coli O157:H7, with 35 of these hospitalized and 11 with Haemolytic Uremic Syndrome (HUS) (see below).

Econiche is manufactured in the Bioniche production facility in Belleville, Ontario, where a $25-million expansion is taking place, supported by the Ontario and Canadian governments. Vaccine supply will be limited during this manufacturing expansion period.

About E. coli O157:H7

An estimated 100,000 cases of human infection with the E. coli O157:H7 organism are reported each year in North America. Two to seven per cent of those people develop haemolytic uremic syndrome (HUS), a disease characterized by kidney failure. Five percent of HUS patients die, many of them children and senior citizens, whose kidneys are more sensitive to damage.

In addition to being infected by contaminated food or water, individuals can become infected from E. coli O157:H7 by visiting animal exhibits. Petting zoos, fairs, and agricultural exhibits provide many possible routes of transmission for E. coli. Direct animal contact is the obvious route, but contact with contaminated products (e.g., sawdust, shavings, soiled clothing or shoes) can also lead to human infection.

About Econiche

Econiche received international recognition in September 2007 by the Animal Pharm Industry Excellence Awards as the best new veterinary product for livestock globally. The vaccine has been developed by a strategic alliance formed in 2000 between the University of British Columbia (UBC), the Alberta Research Council (ARC), the University of Saskatchewan's Vaccine & Infectious Disease Organization (VIDO), and Bioniche, which holds the rights for worldwide commercialization of the vaccine. The vaccine prevents the E. coli O157 bacteria from attaching to the intestines of vaccinated cattle, thereby reducing their reproduction within the animal, and reducing the amount of bacteria that can be released through cattle manure in the environment. More than 30,000 cattle have been involved in clinical testing of the vaccine.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.

Back to top
'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Canadian researchers study mass gatherings and risks of infectious disease threats
2. Canadian Health Organization Deploys IceWEB GIS To Track H1N1 Flu Pandemic
3. Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America
4. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
5. Tamiflu-Resistant Swine Flu Found in Canadian Father
6. Canadian Cancer Society Selects Branded Merchandise Solutions From Boundless Network
7. Smart Post Brings Scrubs & Beyond to Canadian Doorsteps
8. Life Insurance Firms Refusing to Insure Swine Flu Victims says major Canadian insurance broker
9. Charitable Giving for U.S. Health Care Rises a Tepid $241 Million in 2008, While Canadian Charitable Giving Plunges 13 Percent, Association for Healthcare Philanthropy Reports
10. Canadian scientists link fat hormone to death from potentially deadly blood infection
11. Canadian Cardiovascular Society recognizes trailblazing work by U of Alberta heart researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: